INLURIYO™ (imlunestrant) FDA-Approved for Treatment of ER+, HER2-, ESR1-Mutated Advanced or Metastatic Breast Cancer, Available at Biologics by McKesson
Cary, N.C. , Oct. 1, 2025 – Biologics by McKesson, an independent specialty pharmacy specializing in oncology and rare disease […]
PALSONIFY™ (paltusotine), FDA-Approved for Treatment of Adults with Acromegaly Who Had an Inadequate Response to Surgery and/or for Whom Surgery Is Not an Option, Available at Biologics by McKesson
Cary, N.C. , Sept. 25, 2025 – Biologics by McKesson, an independent specialty pharmacy specializing in oncology and rare disease […]
Precigen Selects McKesson to Support Specialty Pharmacy and Patient Hub Services for Launch of Novel Immunotherapy
CARY, N.C., Sept. 25, 2025 – Biologics by McKesson, in partnership with Inspirogene by McKesson, has been chosen by Precigen […]
InspiroGene by McKesson Selected as the Specialty Pharmacy Partner for Iovance’s Amtagvi®—First Cell Therapy Approved for Solid Tumors
CARY, N.C., Sept. 24, 2025 – Biologics by McKesson is proud to announce the launch of Amtagvi® (lifileucel), the newest […]
WAYRILZ™ (rilzabrutinib), FDA-Approved for Treatment of Adults with Immune Thrombocytopenia, Available at Biologics by McKesson
Cary, N.C. , Sept. 10, 2025 – Biologics by McKesson, an independent specialty pharmacy specializing in oncology and rare disease […]
PIQRAY® (alpelisib) FDA Approved for the Treatment of Patients with a PIK3CA Mutation in HR+/HER2- Advanced Breast Cancer , Available Exclusively at Biologics by McKesson
Cary, N.C., August 7, 2025 – Effective June 15, PIQRAY® (alpelisib) is now exclusively available at Biologics by McKesson, an […]
VIJOICE® (alpelisib) FDA Approved for the Treatment of Patients with PIK3CA-Related Overgrowth Spectrum (PROS), Available Exclusively at Biologics by McKesson
Cary, N.C. , August 7, 2025 – Effective June 15, VIJOICE® (alpelisib) is now exclusively available at Biologics by McKesson, […]
ENSACOVE™ (ensartinib), FDA-Approved Treatment for Adult Patients with Advanced ALK-Positive Non-Small Cell Lung Cancer, Exclusively Available at Biologics by McKesson
Cary, N.C. , July 14, 2025 – Biologics by McKesson, an independent specialty pharmacy specializing in oncology and rare disease […]
AUGTYRO™ (Repotrectinib), FDA Approved for Treatment of AdvancedROS1-Positive & NTRK-Positive NSCLC, Available at Biologics by McKessonSpecialty Pharmacy in Limited Distribution Network
Cary, N.C., July 1, 2025 – Effective July 1st, Bristol Myers Squibb Co. has reduced its specialty pharmacy network for […]
IBTROZI™ (Taletrectinib), FDA-Approved Treatment, Available at Biologics by McKesson
Cary, N.C. , June 11, 2025 – Biologics by McKesson, an independent specialty pharmacy specializing in oncology and rare disease […]